Physician
Latrobe Area Hospital, INC.
Latrobe Area Hospital, INC. was paid $348K by Medicaid between Mar 2021 and Dec 2022, across 120 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoLATROBE AREA HOSPITAL, INC.
LATROBE, PA 15650
LATROBE, PA 15650
33aNPI1336166974assigned 07/17/2006
33bProvider typeFamily Medicine Physician
28Total paid$348K
24GClaims19,292
24DCodes billed120
24AFirst – last monthMar 2021 – Dec 2022
Compared with peers
Next to other Family Medicine Physician providers in Pennsylvania
Rank by total paid#212 of 2,756
Median peer was paid$19K
This provider vs. median18×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 12,971 | $347K | |
| 2022 | 6,321 | $615.90 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 372 | 357 | $61K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 370 | 351 | $44K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 10% | 415 | 403 | $36K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.2% | 306 | 300 | $25K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 100 | 99 | $18K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 5.1% | 381 | 121 | $18K |
| 87428 | 2.9% | 181 | 177 | $10K | |
| 80050 | General health panel | 2.2% | 158 | 157 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 217 | 203 | $7K |
| 80053 | Comprehensive metabolic panel | 1.6% | 579 | 547 | $6K |
| 80061 | Lipid panel | 1.4% | 331 | 329 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 602 | 540 | $5K |
108 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 978 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 83 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 311 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 127 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 46 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.1% | 45 | $4K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.1% | 110 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 138 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.0% | 138 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 181 | $3K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 75 | $3K |
| 97161 | <1% | 50 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 39 | $3K |
| 71271 | <1% | 28 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 16 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 225 | $2K |
| 87797 | <1% | 78 | $2K | |
| 87480 | <1% | 78 | $2K | |
| 87660 | <1% | 78 | $2K | |
| 80076 | <1% | 214 | $2K | |
| 84466 | <1% | 99 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 65 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 127 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 221 | $2K |
| 76642 | <1% | 33 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 41 | $2K |
| 82728 | <1% | 109 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 178 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 30 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 25 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 154 | $1K |
| 86618 | <1% | 50 | $1K | |
| 82607 | <1% | 89 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 28 | $1K |
| 84484 | <1% | 123 | $1K | |
| 71250 | <1% | 14 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 46 | $1K |
| 88342 | <1% | 18 | $960.96 | |
| 84153 | <1% | 35 | $944.18 | |
| 86803 | <1% | 42 | $909.72 | |
| 83540 | <1% | 96 | $888.01 | |
| 83690 | <1% | 174 | $855.00 | |
| 81001 | <1% | 282 | $831.06 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 62 | $810.54 |
| 83735 | <1% | 119 | $810.46 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 46 | $767.44 |
| 84439 | <1% | 76 | $656.64 | |
| 82570 | <1% | 82 | $644.64 | |
| 85027 | <1% | 92 | $642.75 | |
| 84702 | <1% | 34 | $636.48 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 29 | $591.28 |
| 87081 | <1% | 105 | $569.28 | |
| 82043 | <1% | 63 | $565.44 | |
| 82784 | <1% | 27 | $498.10 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 13 | $438.13 |
| 85610 | <1% | 112 | $411.23 | |
| 74018 | <1% | 35 | $392.50 | |
| 73630 | <1% | 32 | $390.03 | |
| 73130 | <1% | 29 | $386.75 | |
| 87186 | <1% | 35 | $337.44 | |
| 73030 | <1% | 17 | $324.47 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 34 | $318.06 |
| 86038 | <1% | 18 | $307.80 | |
| 85379 | <1% | 27 | $302.00 | |
| 73610 | <1% | 16 | $289.36 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $285.35 |
| 85652 | <1% | 92 | $273.60 | |
| 87040 | <1% | 25 | $271.32 | |
| 83615 | <1% | 34 | $270.60 | |
| 82746 | <1% | 20 | $259.92 | |
| 86140 | <1% | 78 | $232.56 | |
| 85730 | <1% | 25 | $222.30 | |
| 73110 | <1% | 13 | $173.71 | |
| 82565 | <1% | 22 | $160.82 | |
| 83655 | <1% | 13 | $148.20 | |
| 84703 | <1% | 13 | $140.40 | |
| 86431 | <1% | 14 | $123.34 | |
| 84520 | <1% | 19 | $117.80 | |
| 87077 | <1% | 14 | $113.26 | |
| 87070 | <1% | 15 | $110.18 | |
| 84550 | <1% | 15 | $106.65 | |
| 81025 | <1% | 37 | $86.64 | |
| 82948 | <1% | 83 | $63.84 | |
| 86592 | <1% | 13 | $50.16 | |
| J2704 | Injection, propofol, 10 mg | 0% | 899 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 452 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 909 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 603 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 406 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| 0011A | 0% | 13 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 213 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 1,267 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 142 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 465 | $0.00 |
| J3490 | Unclassified drugs | 0% | 245 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 28 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 38 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 85 | $0.00 |
| A9270 | Non-covered item or service | 0% | 39 | $0.00 |
| 96376 | 0% | 41 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,230 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 634 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 129 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 497 | $0.00 |
| 83516 | 0% | 12 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 57 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 85 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDISHONG, MELISSA (VICE PRESIDENT/EXEC DIR - EHPP)
Parent organizationLATROBE AREA HOSPITAL, INC.
| Provider | Location | Paid |
|---|---|---|
| Excela Health Physician Practices INC | Greensburg, PA | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.